Therapy for myeloproliferative neoplasms: when, which agent, and how?
HL Geyer, RA Mesa - Blood, The Journal of the American …, 2014 - ashpublications.org
Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia,
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
S Verstovsek, CC Chen, M Egyed, M Ellis, L Fox… - Future …, 2021 - Taylor & Francis
Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and
splenomegaly. Anemia and transfusion dependency are among the most important negative …
splenomegaly. Anemia and transfusion dependency are among the most important negative …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the E uropean U nion
O Moulard, J Mehta, J Fryzek, R Olivares… - European journal of …, 2014 - Wiley Online Library
Background Primary myelofibrosis (PMF), essential thrombocythemia (ET), and
polycythemia vera (PV) are BCR ABL‐negative myeloproliferative neoplasms (MPN) …
polycythemia vera (PV) are BCR ABL‐negative myeloproliferative neoplasms (MPN) …
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring …
RM Emanuel, AC Dueck, HL Geyer… - Journal of clinical …, 2012 - ascopubs.org
Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and
alleviation of this burden represents a paramount treatment objective in the development of …
alleviation of this burden represents a paramount treatment objective in the development of …
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
G Barosi, R Mesa, G Finazzi, C Harrison… - Blood, The Journal …, 2013 - ashpublications.org
Standardized response criteria to interpret and compare clinical trials are needed for
approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet …
approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet …
Epidemiology of myeloproliferative neoplasms in the United States
J Mehta, H Wang, SU Iqbal, R Mesa - Leukemia & lymphoma, 2014 - Taylor & Francis
Abstract Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are
three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs) …
three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs) …
Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera
T Barbui, AM Vannucchi, V De Stefano… - NEJM …, 2023 - evidence.nejm.org
Background Whether phlebotomy alone can adequately maintain target hematocrit in
patients with low-risk polycythemia vera (PV) remains elusive. Methods In a phase 2 open …
patients with low-risk polycythemia vera (PV) remains elusive. Methods In a phase 2 open …
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey
Abstract Background The Philadelphia chromosome− negative myeloproliferative
neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential …
neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential …
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke, K Begna… - Leukemia, 2013 - nature.com
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …